Premium
Modulatory effect of intravenous immunoglobulin on Th17/Treg cell balance in women with unexplained recurrent spontaneous abortion
Author(s) -
Muyayalo Kahinho P.,
Li ZhiHui,
Mor Gil,
Liao AiHua
Publication year - 2018
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/aji.13018
Subject(s) - medicine , abortion , immunology , immune system , antibody , pregnancy , treg cell , cell , t cell , biology , il 2 receptor , genetics
Recurrent spontaneous abortion ( RSA ) is a growing problem worldwide. In a majority of cases, the cause remains unknown but there is increasing evidence that immunologic factors play an important role. Intravenous immunoglobulin ( IVI g) therapy has been proposed to have immune modulatory effects and therefore been applicable for the treatment of patients with RSA . Although its efficacy is still controversial, several recent studies suggest that IVI g treatment may improve pregnancy outcomes. CD 4 + T cells and their related cytokines play an important role in maternal‐fetal immune regulation, and an imbalance of Th17/Treg cell ratio has been proposed as a cause for RSA . We review the scientific evidence supporting a modulatory effect of IVI g on Th17/Treg cell balance and discuss the potential mechanisms how IVI g might enhance Treg cells function. We propose that correction of Th17/Treg cell dysregulation could be one of the mechanisms that can explain the positive therapeutic effects of IVI g therapy. Consequently, selecting patients with abnormal Th17/Treg cell ratios could increase the success of IVI g therapy.